TY - JOUR
T1 - Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group
AU - Ehrhardt, Matthew J.
AU - Leerink, Jan M.
AU - Mulder, Renée L.
AU - Mavinkurve-Groothuis, Annelies
AU - Kok, Wouter
AU - Nohria, Anju
AU - Nathan, Paul C.
AU - Merkx, Remy
AU - de Baat, Esmée
AU - Asogwa, Ogechukwu A.
AU - Skinner, Roderick
AU - Wallace, Hamish
AU - Lieke Feijen, E. A.M.
AU - de Ville de Goyet, Maëlle
AU - Prasad, Maya
AU - Bárdi, Edit
AU - Pavasovic, Vesna
AU - van der Pal, Helena
AU - Fresneau, Brice
AU - Demoor-Goldschmidt, Charlotte
AU - Hennewig, Ulrike
AU - Steinberger, Julia
AU - Plummer, Chris
AU - Chen, Ming Hui
AU - Teske, Arco J.
AU - Haddy, Nadia
AU - van Dalen, Elvira C.
AU - Constine, Louis S.
AU - Chow, Eric J.
AU - Levitt, Gill
AU - Hudson, Melissa M.
AU - Kremer, Leontien C.M.
AU - Armenian, Saro H.
N1 - Funding Information:
We thank Tracie Gatewood for her administrative support in the preparation of this manuscript.
Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/3
Y1 - 2023/3
N2 - Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020.
AB - Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020.
UR - http://www.scopus.com/inward/record.url?scp=85148722303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148722303&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(23)00012-8
DO - 10.1016/S1470-2045(23)00012-8
M3 - Review article
C2 - 37052966
AN - SCOPUS:85148722303
SN - 1470-2045
VL - 24
SP - e108-e120
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 3
ER -